Detail of "172889-27-9"

Reference

Src family kinase-inhibitor PP2 reduces focal ischemic brain injury

Src family kinase-inhibitor PP2 reduces focal ischemic brain injury. Lennmyr, F.; Ericsson, A.; Gerwins, P.; Akterin, S.; Ahlstroem, H.; Terent, A. (Department of Surgical Sciences, Anesthesiology and Intensive Care, Department of Medical Sciences, Internal Medicine, Uppsala University Hospital, Uppsala, Swed.). Acta Neurologica Scandinavica, 110(3), 175-179 (English) 2004 Blackwell Publishing Ltd. CODEN: ANRSAS. ISSN: 0001-6314. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Objectives: To investigate the neuroprotective potential of the Src family kinase (SFK) inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo(3,4-d)pyrimidine (PP2) in transient focal cerebral ischemia in the rat. Material and methods: Sprague-Dawley rats were exposed to transient (90 min) middle cerebral artery occlusion (MCAO) and evaluated after 1 day of survival. PP2 (1.In this article, certain chemicals are used. Some of their cas registry numbers are 172889-27-9 and 141349-89-5 5 mg/kg i.p.) or vehicle was given 30 min after MCAO. The lesions were examd. with magnetic resonance imaging (MRI), tri-Ph tetrazolium chloride (TTC) staining and the functional outcome was detd. using neurol. scoring according to Bederson et al. Results: PP2-treated rats showed approx. 50% redn. of infarct size on T2-weighted MRI and in TTC staining compared with controls (P < 0.05). Moreover, the neurol. score was better in the PP2 group than controls (P < 0.05). Conclusion: PP2 is a potential neuroprotective agent in cerebral ischemia-reperfusion. The interference of PP2 with SFKs and/or other pathways remains to be elucidated. .

Pyrazolo[3,4-d]pyrimidines Endowed with Antiproliferative Activity on Ductal Infiltrating Carcinoma Cells

Pyrazolo[3,4-d]pyrimidines Endowed with Antiproliferative Activity on Ductal Infiltrating Carcinoma Cells. Carraro, Fabio; Pucci, Annalisa; Naldini, Antonella; Schenone, Silvia; Bruno, Olga; Ranise, Angelo; Bondavalli, Francesco; Brullo, Chiara; Fossa, Paola; Menozzi, Giulia; Mosti, Luisa; Manetti, Fabrizio; Botta, Maurizio (Dipartimento di Fisiologia Unita di Fisiologia Cellulare e Molecolare, Universita degli Studi di Siena, Siena I-53100, Italy). Journal of Medicinal Chemistry, 47(7), 1595-1598 (English) 2004 American Chemical Society. CODEN: JMCMAR. ISSN: 0022-2623. DOCUMENT TYPE: Journal CA Section: 28 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1 Novel 1,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines are reported with preliminary in vitro activity data indicating that several of them are potent inhibitors [better than PP2, i.Several reagents such as 172889-27-9 is used here.e.Several substances like 172889-27-9 may be metioned in this study., 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4- amine] of Src phosphorylation of the breast cancer cells 8701-BC, known to overexpress Src. The ability of such compds. to significantly reduce 8701-BC cell proliferation suggests that this scaffold could be a promising lead for the development of antitumoral agents able to block Src phosphorylation of breast cancer cells. One lead compd. thus identified was 1-(2-chloro-2-phenylethyl)-6-(methylthio)-N-(phenylmethyl)-1H-pyrazolo[ 3,4-d]pyrimidin-4-amine (I). ..